201 related articles for article (PubMed ID: 31385744)
1. Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer.
Shariat SF; Enikeev DV; Mostafaei H
Immunotherapy; 2019 Sep; 11(13):1083-1086. PubMed ID: 31385744
[No Abstract] [Full Text] [Related]
2. Salvage Therapies for Non-muscle-invasive Bladder Cancer: Who Will Respond to Bacillus Calmette-Guérin? Predictors and Nomograms.
Faba ÓR; Pisano F; Krajewski W; Breda A; Palou J
Urol Clin North Am; 2020 Feb; 47(1):5-13. PubMed ID: 31757300
[TBL] [Abstract][Full Text] [Related]
3. Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.
Becker REN; Kates MR; Bivalacqua TJ
Urol Clin North Am; 2020 Feb; 47(1):15-21. PubMed ID: 31757296
[TBL] [Abstract][Full Text] [Related]
4. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
J Urol; 2018 Jun; 199(6):1446-1451. PubMed ID: 29307686
[TBL] [Abstract][Full Text] [Related]
5. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
[TBL] [Abstract][Full Text] [Related]
6. Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette-Guérin Immunotherapy of Bladder Cancer.
Ibrahim OM; Kalinski P
Cells; 2024 Apr; 13(8):. PubMed ID: 38667314
[TBL] [Abstract][Full Text] [Related]
7. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
8. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
9. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
11. Quadruple immunotherapy of Bacillus Calmette-Guérin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non-muscle-invasive bladder cancer.
Steinberg RL; Nepple KG; Velaer KN; Thomas LJ; O'Donnell MA
Urol Oncol; 2017 Dec; 35(12):670.e7-670.e14. PubMed ID: 28801026
[TBL] [Abstract][Full Text] [Related]
12. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
13. Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.
Konety BR; Narayan VM; Dinney CPN
Urol Clin North Am; 2020 Feb; 47(1):1-4. PubMed ID: 31757292
[TBL] [Abstract][Full Text] [Related]
14. Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
Rentsch CA; Derré L; Dugas SG; Wetterauer C; Federer-Gsponer JR; Thalmann GN; Ingersoll MA
Eur Urol Focus; 2018 Jul; 4(4):485-493. PubMed ID: 30415921
[TBL] [Abstract][Full Text] [Related]
15. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Mukherjee N; Svatek RS; Mansour AM
Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
[TBL] [Abstract][Full Text] [Related]
16. Bacillus Calmette-Guérin in the Treatment of Tuberculosis and Bladder Cancer: Clinical Use and Immunologic Response. Reports of a workshop. Toronto, Canada, 11-13 July 1994.
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S59-121. PubMed ID: 11153467
[No Abstract] [Full Text] [Related]
17. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells.
Carretero R; Cabrera T; Gil H; Saenz-Lopez P; Maleno I; Aptsiauri N; Cozar JM; Garrido F
Int J Cancer; 2011 Aug; 129(4):839-46. PubMed ID: 20957629
[TBL] [Abstract][Full Text] [Related]
20. Intravesical bacillus Calmette-Guérin instillation in non-muscle-invasive bladder cancer: A review.
Saluja M; Gilling P
Int J Urol; 2018 Jan; 25(1):18-24. PubMed ID: 28741703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
